Recent media moments have thrust Tourette syndrome back into the public spotlight, but not always in ways that reflect the lived realities of those who experience it. While controversy often drives attention, it rarely creates understanding. This first installment reframes that moment by grounding the conversation in clinical context, personal experience, and current limitations of treatment, with the goal of moving beyond sensationalism toward clarity and compassion in honor of Tourette Syndrome Awareness Month.
Media Attention on Tourette Syndrome and the Need for Clinical Context
Tourette syndrome (often referred to simply as Tourette) made headlines in February following a series of high-profile and controversial moments. At the British Academy of Film and Television Arts (BAFTA) awards, a Tourette advocate who had inspired a nominated film experienced an unfortunate involuntary verbal tick that included an audible racial slur during the ceremony, sparking outrage from high-profile actors. This was followed by a Saturday Night Live skit portraying celebrities excusing inappropriate behavior by attributing it to Tourette. The sketch drew strong criticism from the Tourette community.
As a scientist and science communicator who lives with Tourette syndrome, these events felt like a timely opportunity to shift the conversation. Rather than focusing solely on controversy, I want to highlight meaningful developments in Tourette syndrome research and underscore the importance of public education for those who live with the condition. But first, it is essential to establish a shared clinical foundation.
The disruptive nature of a tic should not be conflated with the character of the person experiencing it.
Clinical Features and Lived Experience of Tourette Syndrome
Tourette syndrome is a neurodevelopmental disorder characterized by involuntary motor and vocal tics that begin in childhood and often persist into adulthood. It affects approximately 1 in 300 children and adolescents, with higher prevalence among male individuals. Tic frequency, severity, and complexity vary widely, resulting in minimal functional impact on some individuals and substantial challenges for others.
Diagnostic criteria require the presence of both motor and vocal tics, which are accompanied by a premonitory urge (a sensory phenomenon commonly described as “an itch that needs to be scratched”). In other words, it is an internal pressure that builds until the tic is performed. Although it may be possible to resist the urge briefly, the sensation usually builds. After performing the tic, the urge subsides, sometimes only briefly, after which it can build again leading to another tic.
Coprolalia, the involuntary utterance of obscenities, is the symptom most closely associated with Tourette syndrome in popular culture, despite it occurring in only 10 to 20 percent of individuals with the condition. (Coprolalia is what occurred at the BAFTAs.) While I have not personally experienced coprolalia, it is well understood within the medical community that these vocalizations are intrusive and do not reflect an individual’s beliefs, values, or intent.
My own experience highlights how context and stress modulate tic expression. My vocal tics are more pronounced in quiet environments such as classrooms, libraries, or movie theaters, where even minor sounds feel amplified. My motor tics also increase in situations where they are highly visible, such as haircuts or dental appointments. The anticipation of being noticed heightens stress and anxiety, further reducing the feasibility of suppression. Importantly, the disruptive nature of a tic should not be conflated with the character of the person experiencing it.
Neurobiology of Tourette Syndrome and Treatment Limitations
Despite decades of research, the precise causes and pathophysiology of Tourette syndrome remain incompletely understood. Current evidence suggests contributions from altered neuronal development and connectivity, impaired inhibitory signaling in brain regions critical for voluntary movement, and dysregulated neurotransmitter systems, particularly dopamine and GABA. Ongoing research aims to clarify the relative contributions of these mechanisms.
Management strategies are guided by symptom severity and may include behavioral, pharmacologic, and occasionally surgical interventions in select cases. Pharmacologic treatments often target dopamine signaling, with low-dose dopamine D2‑receptor antagonists approved in the United States and recommended when behavioral interventions fail to adequately control tics. However, adverse effects frequently limit their clinical utility, which I can also speak to from personal experience.
The height of my symptom severity was during my first year of college, exacerbated by the stress (good and bad) of moving away from home to an unfamiliar environment. My doctor supported my wishes to try medical therapy and prescribed low-dose risperidone, which is a common dopamine D2-receptor antagonist prescribed for Tourette syndrome. Unfortunately, the medication produced minimal (if any) tic improvement and caused lethargy and brain fog. Even if I had seen tic improvement, I probably would have discontinued the treatment given the adverse effects. This experience reflects a broader clinical challenge: treatment efficacy must be balanced against quality-of-life costs.
Toward a Better Understanding of Tourette
Tourette syndrome is far more complex than its narrow and often sensationalized portrayals. A meaningful shift in perception requires understanding the neurobiology of tics, the diversity of symptom presentation, and the lived experience of both the condition and its treatments. As new therapies emerge, progress will depend not only on scientific advances, but also on informed, compassionate public discourse.
Stay tuned for Part 2, where I examine emerging research advances and future directions for treatment and understanding of Tourette syndrome.
